173 related articles for article (PubMed ID: 27035498)
1. Omalizumab's Impact on Total and Allergen-Specific IgE Levels: A Polyclonal Story.
Eckl-Dorna J
Int Arch Allergy Immunol; 2016; 169(2):69-70. PubMed ID: 27035498
[No Abstract] [Full Text] [Related]
2. Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma.
Mizuma H; Tanaka A; Uchida Y; Fujiwara A; Manabe R; Furukawa H; Kuwahara N; Fukuda Y; Kimura T; Jinno M; Ohta S; Yamamoto M; Matsukura S; Adachi M; Sagara H
Int Arch Allergy Immunol; 2015; 168(3):165-72. PubMed ID: 26790100
[TBL] [Abstract][Full Text] [Related]
3. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.
Samitas K; Delimpoura V; Zervas E; Gaga M
Eur Respir Rev; 2015 Dec; 24(138):594-601. PubMed ID: 26621973
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
5. Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab.
Gon Y; Ito R; Maruoka S; Mizumura K; Kozu Y; Hiranuma H; Iida Y; Hikichi M; Shikano S; Hashimoto S
Allergol Int; 2018 Apr; 67(2):283-285. PubMed ID: 28927962
[No Abstract] [Full Text] [Related]
6. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma.
Tat TS; Cilli A
Ann Allergy Asthma Immunol; 2016 Nov; 117(5):546-549. PubMed ID: 27788886
[TBL] [Abstract][Full Text] [Related]
8. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.
Forbush JT; Banks TA
Ann Allergy Asthma Immunol; 2016 Sep; 117(3):335-7. PubMed ID: 27613470
[No Abstract] [Full Text] [Related]
10. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
11. IgE-mediated asthma: New revelations and future insights.
Djukanovic R; Hanania N; Busse W; Price D
Respir Med; 2016 Mar; 112():128-9. PubMed ID: 26577335
[TBL] [Abstract][Full Text] [Related]
12. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in the Therapy of Pediatric Asthma.
Poddighe D; Brambilla I; Licari A; Marseglia GL
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):103-109. PubMed ID: 29714140
[TBL] [Abstract][Full Text] [Related]
15. The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
Bartuzi Z; Bodzenta-Łukaszyk A; Kuna P; Kupryś-Lipińska I; Niżankowska-Mogilnicka E; Samoliński B
Pneumonol Alergol Pol; 2015; 83(4):335-8. PubMed ID: 26166795
[No Abstract] [Full Text] [Related]
16. Omalizumab treatment in asthma-COPD overlap syndrome.
Tat TS; Cilli A
J Asthma; 2016 Dec; 53(10):1048-50. PubMed ID: 27144514
[TBL] [Abstract][Full Text] [Related]
17. Influence of Staphylococcal enterotoxin-specific IgE sensitization on therapeutic efficacy of omalizumab therapy in severe asthma.
Weng CM; Wu WC; Lee MJ; Chen MC; Chou CL; Lin CY; Chung KF; Kuo HP
Respirology; 2024 Mar; 29(3):252-255. PubMed ID: 38296607
[No Abstract] [Full Text] [Related]
18. Eosinophilic Esophagitis Onset Despite Six Years' Treatment With Omalizumab in an Asthmatic Patient: No Protective Effect for Anti-IgE Therapy?
Franceschini L; Macchiarelli R; Biviano I; Farsi A
Am J Gastroenterol; 2021 Jul; 116(7):1560. PubMed ID: 33852452
[No Abstract] [Full Text] [Related]
19. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
20. Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab.
Roth M; Zhao F; Zhong J; Lardinois D; Tamm M
PLoS One; 2015; 10(9):e0136549. PubMed ID: 26332463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]